News tagged with insufficient response

Rituximab promotes long-term response for patients with immune destruction of platelets

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of ...

Pediatrics May 07, 2012 | not rated yet | 0